publication venue for
- Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction. 2023
- The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD. 2021
- Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice.. 34. 2020
- Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.. 33. 2019
- Barriers to Beta-Blocker Use and Up-Titration Among Patients with Heart Failure with Reduced Ejection Fraction.. 31. 2017
- Primary Care Physician Perspectives on Barriers to Statin Treatment.. 31. 2017
- Burden of Coronary Heart Disease Rehospitalizations Following Acute Myocardial Infarction in Older Adults.. 30. 2016
- Memory T Cells Mediate Cardiac Allograft Vasculopathy and are Inactivated by Anti-OX40L Monoclonal Antibody.. 28. 2014
- Predictors of adherence to statins for primary prevention.. 21. 2007
- Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity.. 14. 2000
- Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs.. 9. 1995
- Effects of acetyl strophanthidin on duration of atrial fibrillation in the neurally-intact and blockaded dog.. 2. 1988
- Vasoconstriction induced by ouabain in the canine coronary artery: contribution of adrenergic and nonadrenergic responses.. 2. 1988
- Metabolic effects of isradipine in non-insulin-dependent diabetes mellitus (NIDDM) hypertensive patients.. 9. 1995
- Lipid-lowering therapy in patients with average cholesterol and high cardiovascular risk, insights from the Heart Protection Study. 2004